Yosef Yarden

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Mosesson Yaron; Chetrit David; Schley Leehee; Berghoff Janina; Ziv Tamar; Carvalho Silvia; Milanezi Fernanda; Admon Arie; Schmitt Fernando; Ehrlich Marcelo; Yarden Yosef
Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling.
Zwang Yaara; Yarden Yosef
Systems biology of growth factor-induced receptor endocytosis.
Ben-Kasus Tsipi; Schechter Bilha; Lavi Sara; Yarden Yosef; Sela Michael
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Yosef Yarden (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Mosesson Yaron; Chetrit David; Schley Leehee; Berghoff Janina; Ziv Tamar; Carvalho Silvia; Milanezi Fernanda; Admon Arie; Schmitt Fernando; Ehrlich Marcelo; Yarden Yosef
Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling.
Developmental cell 2009;16(5):687-98.
2009: Zwang Yaara; Yarden Yosef
Systems biology of growth factor-induced receptor endocytosis.
Traffic (Copenhagen, Denmark) 2009;10(4):349-63.
2009: Ben-Kasus Tsipi; Schechter Bilha; Lavi Sara; Yarden Yosef; Sela Michael
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(9):3294-9.
2008: Mosesson Yaron; Mills Gordon B; Yarden Yosef
Derailed endocytosis: an emerging feature of cancer.
Nature reviews. Cancer 2008;8(11):835-50.
2008: Shema Efrat; Tirosh Itay; Aylon Yael; Huang Jing; Ye Chaoyang; Moskovits Neta; Raver-Shapira Nina; Minsky Neri; Pirngruber Judith; Tarcic Gabi; Hublarova Pavla; Moyal Lilach; Gana-Weisz Mali; Shiloh Yosef; Yarden Yossef; Johnsen Steven A; Vojtesek Borivoj; Berger Shelley L; Oren Moshe
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
Genes & development 2008;22(19):2664-76.
2007: Shtiegman K; Kochupurakkal B S; Zwang Y; Pines G; Starr A; Vexler A; Citri A; Katz M; Lavi S; Ben-Basat Y; Benjamin S; Corso S; Gan J; Yosef R B; Giordano S; Yarden Y
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling.
Oncogene 2007;26(49):6968-78.
2007: Katz Menachem; Amit Ido; Citri Ami; Shay Tal; Carvalho Silvia; Lavi Sara; Milanezi Fernanda; Lyass Ljuba; Amariglio Ninette; Jacob-Hirsch Jasmine; Ben-Chetrit Nir; Tarcic Gabi; Lindzen Moshit; Avraham Roi; Liao Yi-Chun; Trusk Patricia; Lyass Asya; Rechavi Gideon; Spector Neil L; Lo Su Hao; Schmitt Fernando; Bacus Sarah S; Yarden Yosef
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.
Nature cell biology 2007;9(8):961-9.
2007: Katz Menachem; Amit Ido; Yarden Yosef
Regulation of MAPKs by growth factors and receptor tyrosine kinases.
Biochimica et biophysica acta 2007;1773(8):1161-76.
2007: Ben-Kasus Tsipi; Schechter Bilha; Sela Michael; Yarden Yosef
Cancer therapeutic antibodies come of age: targeting minimal residual disease.
Molecular oncology 2007;1(1):42-54.
2007: Spector Neil L; Yarden Yosef; Smith Bradley; Lyass Ljuba; Trusk Patricia; Pry Karen; Hill Jason E; Xia Wenle; Seger Rony; Bacus Sarah S
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(25):10607-12.
2007: Ben-Yosef Rami; Starr Alex; Karaush Victoria; Loew Vered; Lev-Ari Shahar; Barnea Itay; Lidawi Ghalib; Shtabsky Alexander; Greif Yoel; Yarden Yosef; Vexler Akiva
ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy.
The Prostate 2007;67(8):871-80.
2007: Amit Ido; Citri Ami; Shay Tal; Lu Yiling; Katz Menachem; Zhang Fan; Tarcic Gabi; Siwak Doris; Lahad John; Jacob-Hirsch Jasmine; Amariglio Ninette; Vaisman Nora; Segal Eran; Rechavi Gideon; Alon Uri; Mills Gordon B; Domany Eytan; Yarden Yosef
A module of negative feedback regulators defines growth factor signaling.
Nature genetics 2007;39(4):503-12.
2007: Bublil Erez M; Yarden Yosef
The EGF receptor family: spearheading a merger of signaling and therapeutics.
Current opinion in cell biology 2007;19(2):124-34.
2007: Amit Ido; Wides Ron; Yarden Yosef
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.
Molecular systems biology 2007;3():151.
2006: Zwang Yaara; Yarden Yosef
p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy.
The EMBO journal 2006;25(18):4195-206.
2006: Germano Serena; Barberis Davide; Santoro Massimo M; Penengo Lorenza; Citri Ami; Yarden Yosef; Gaudino Giovanni
Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling.
The Journal of biological chemistry 2006;281(31):21710-9.
2006: Oved Shlomo; Mosesson Yaron; Zwang Yaara; Santonico Elena; Shtiegman Keren; Marmor Mina D; Kochupurakkal Bose S; Katz Menachem; Lavi Sara; Cesareni Gianni; Yarden Yosef
Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases.
The Journal of biological chemistry 2006;281(31):21640-51.
2006: Citri Ami; Yarden Yosef
EGF-ERBB signalling: towards the systems level.
Nature reviews. Molecular cell biology 2006;7(7):505-16.
2006: Starr Alex; Greif Joel; Vexler Akiva; Ashkenazy-Voghera Maia; Gladesh Valery; Rubin Chanan; Kerber Gabriele; Marmor Sylvia; Lev-Ari Shahar; Inbar Moshe; Yarden Yosef; Ben-Yosef Rami
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy.
International journal of cancer. Journal international du cancer 2006;119(2):269-74.
2006: Li Rong; Soosairajah Juliana; Harari Daniel; Citri Ami; Price John; Ng Hooi Ling; Morton Craig J; Parker Michael W; Yarden Yosef; Bernard Ora
Hsp90 increases LIM kinase activity by promoting its homo-dimerization.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006;20(8):1218-20.
2006: Citri Ami; Harari Daniel; Shohat Galit; Ramakrishnan Parameswaran; Gan Judith; Lavi Sara; Eisenstein Miriam; Kimchi Adi; Wallach David; Pietrokovski Shmuel; Yarden Yosef
Hsp90 recognizes a common surface on client kinases.
The Journal of biological chemistry 2006;281(20):14361-9.
2006: Mosesson Yaron; Yarden Yosef
Monoubiquitylation: a recurrent theme in membrane protein transport.
The Israel Medical Association journal : IMAJ 2006;8(4):233-7.
2006: Zsebik Barbara; Citri Ami; Isola Jorma; Yarden Yosef; Szöllosi János; Vereb György
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Immunology letters 2006;104(1-2):146-55.
2006: Katz Menachem; Mosesson Yaron; Yarden Yosef
In vitro and in vivo assays of monoubiquitination of receptor tyrosine kinases.
Methods in molecular biology (Clifton, N.J.) 2006;327():115-29.
2005: Yarden Yosef
[Basic principles of signal transduction]
Onkologie 2005;28 Suppl 4():14-7.
2005: Rubin Chanan; Zwang Yaara; Vaisman Nora; Ron Dina; Yarden Yosef
Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways.
The Journal of biological chemistry 2005;280(10):9735-44.
2005: Kochupurakkal Bose S; Harari Daniel; Di-Segni Ayelet; Maik-Rachline Galia; Lyass Ljuba; Gur Gal; Kerber Gabriele; Citri Ami; Lavi Sara; Eilam Raya; Chalifa-Caspi Vered; Eshhar Zelig; Pikarsky Eli; Pinkas-Kramarski Ronit; Bacus Sarah S; Yarden Yosef
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.
The Journal of biological chemistry 2005;280(9):8503-12.
2005: Friedman Lilach M; Rinon Ariel; Schechter Bilha; Lyass Ljuba; Lavi Sara; Bacus Sarah S; Sela Michael; Yarden Yosef
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(6):1915-20.
2005: Kario Edith; Marmor Mina D; Adamsky Konstantin; Citri Ami; Amit Ido; Amariglio Ninette; Rechavi Gideon; Yarden Yosef
Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling.
The Journal of biological chemistry 2005;280(8):7038-48.
2005: Rubin Chanan; Gur Gal; Yarden Yosef
Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation.
Cell research 2005;15(1):66-71.
2004: Citri Ami; Gan Judith; Mosesson Yaron; Vereb Gyorgi; Szollosi Janos; Yarden Yosef
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.
EMBO reports 2004;5(12):1165-70.
2004: Yarden Yosef; Baselga José; Miles David
Molecular approach to breast cancer treatment.
Seminars in oncology 2004;31(5 Suppl 10):6-13.
2004: Gur Gal; Rubin Chanan; Katz Menachem; Amit Ido; Citri Ami; Nilsson Jonas; Amariglio Ninette; Henriksson Roger; Rechavi Gideon; Hedman Håkan; Wides Ron; Yarden Yosef
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.
The EMBO journal 2004;23(16):3270-81.
2004: Mosesson Yaron; Yarden Yosef
Oncogenic growth factor receptors: implications for signal transduction therapy.
Seminars in cancer biology 2004;14(4):262-70.
2004: Amit Ido; Yakir Liat; Katz Menachem; Zwang Yaara; Marmor Mina D; Citri Ami; Shtiegman Keren; Alroy Iris; Tuvia Shmuel; Reiss Yuval; Roubini Eli; Cohen Maya; Wides Ron; Bacharach Eran; Schubert Ullrich; Yarden Yosef
Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding.
Genes & development 2004;18(14):1737-52.
2004: Marmor Mina D; Yarden Yosef
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases.
Oncogene 2004;23(11):2057-70.
2004: Marmor Mina D; Skaria Kochupurakkal Bose; Yarden Yosef
Signal transduction and oncogenesis by ErbB/HER receptors.
International journal of radiation oncology, biology, physics 2004;58(3):903-13.
2004: Citri Ami; Kochupurakkal Bose S; Yarden Yosef
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.
Cell cycle (Georgetown, Tex.) 2004;3(1):51-60.
2004: Kochupurakkal Bose S; Yarden Yosef
Signaling by growth factor receptors.
Methods in molecular biology (Clifton, N.J.) 2004;250():177-202.
2003: Shelly Maya; Mosesson Yaron; Citri Ami; Lavi Sara; Zwang Yaara; Melamed-Book Naomi; Aroeti Benjamin; Yarden Yosef
Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7.
Developmental cell 2003;5(3):475-86.
2003: Penengo Lorenza; Rubin Chanan; Yarden Yosef; Gaudino Giovanni
c-Cbl is a critical modulator of the Ron tyrosine kinase receptor.
Oncogene 2003;22(24):3669-79.
2003: Mosesson Yaron; Shtiegman Keren; Katz Menachem; Zwang Yaara; Vereb Gyorgi; Szollosi Janos; Yarden Yosef
Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation.
The Journal of biological chemistry 2003;278(24):21323-6.
2003: Citri Ami; Skaria Kochupurakkal Bose; Yarden Yosef
The deaf and the dumb: the biology of ErbB-2 and ErbB-3.
Experimental cell research 2003;284(1):54-65.
2003: Bao Jing; Gur Gal; Yarden Yosef
Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(5):2438-43.
2003: Rubin Chanan; Litvak Vladi; Medvedovsky Helena; Zwang Yaara; Lev Sima; Yarden Yosef
Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops.
Current biology : CB 2003;13(4):297-307.
2003: Shtiegman Keren; Yarden Yosef
The role of ubiquitylation in signaling by growth factors: implications to cancer.
Seminars in cancer biology 2003;13(1):29-40.
2002: Katz Menachem; Shtiegman Keren; Tal-Or Pazit; Yakir Liat; Mosesson Yaron; Harari Daniel; Machluf Yossi; Asao Hironobu; Jovin Thomas; Sugamura Kazuo; Yarden Yosef
Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4.
Traffic (Copenhagen, Denmark) 2002;3(10):740-51.
2002: Citri Ami; Alroy Iris; Lavi Sara; Rubin Chanan; Xu Wanping; Grammatikakis Nicolas; Patterson Cam; Neckers Len; Fry David W; Yarden Yosef
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.
The EMBO journal 2002;21(10):2407-17.
2002: Oved Shlomo; Yarden Yosef
Signal transduction: molecular ticket to enter cells.
Nature 2002;416(6877):133-6.
2002: Waterman Hadassa; Katz Menachem; Rubin Chanan; Shtiegman Keren; Lavi Sara; Elson Ari; Jovin Thomas; Yarden Yosef
A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling.
The EMBO journal 2002;21(3):303-13.
2001: Ettenberg S A; Magnifico A; Cuello M; Nau M M; Rubinstein Y R; Yarden Y; Weissman A M; Lipkowitz S
Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex.
The Journal of biological chemistry 2001;276(29):27677-84.
2001: Yarden Y; Sliwkowski M X
Untangling the ErbB signalling network.
Nature reviews. Molecular cell biology 2001;2(2):127-37.
2001: Waterman H; Yarden Y
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.
FEBS letters 2001;490(3):142-52.
2001: Bacus S S; Gudkov A V; Lowe M; Lyass L; Yung Y; Komarov A P; Keyomarsi K; Yarden Y; Seger R
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Oncogene 2001;20(2):147-55.
2001: Yarden Y
Biology of HER2 and its importance in breast cancer.
Oncology 2001;61 Suppl 2():1-13.
2001: Rubin I; Yarden Y
The basic biology of HER2.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12 Suppl 1():S3-8.
2000: Vaisman N; Nissim A; Klapper L N; Tirosh B; Yarden Y; Sela M
Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library.
Immunology letters 2000;75(1):61-7.
2000: Harari D; Yarden Y
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.
Oncogene 2000;19(53):6102-14.
2000: Levkowitz G; Oved S; Klapper L N; Harari D; Lavi S; Sela M; Yarden Y
c-Cbl is a suppressor of the neu oncogene.
The Journal of biological chemistry 2000;275(45):35532-9.
2000: Bao J; Alroy I; Waterman H; Schejter E D; Brodie C; Gruenberg J; Yarden Y
Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome.
The Journal of biological chemistry 2000;275(34):26178-86.
2000: Hurwitz E; Klapper L N; Wilchek M; Yarden Y; Sela M
Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies.
Cancer immunology, immunotherapy : CII 2000;49(4-5):226-34.
2000: Klapper L N; Waterman H; Sela M; Yarden Y
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.
Cancer research 2000;60(13):3384-8.
2000: Chausovsky A; Waterman H; Elbaum M; Yarden Y; Geiger B; Bershadsky A D
Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization.
Oncogene 2000;19(7):878-88.
2000: Bacus S S; Gudkov A V; Esteva F J; Yarden Y
Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response.
Breast disease 2000;11():63-75.
2000: Alroy I; Yarden Y
Biochemistry of HER2 oncogenesis in breast cancer.
Breast disease 2000;11():31-48.
2000: Yarden Y
Breast disease. Introduction.
Breast disease 2000;11():1-3.
2000: Kirschbaum M H; Yarden Y
The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms.
Journal of cellular biochemistry. Supplement 2000;34():52-60.
2000: Klapper L N; Kirschbaum M H; Sela M; Yarden Y
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.
Advances in cancer research 2000;77():25-79.
1999: Levkowitz G; Waterman H; Ettenberg S A; Katz M; Tsygankov A Y; Alroy I; Lavi S; Iwai K; Reiss Y; Ciechanover A; Lipkowitz S; Yarden Y
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.
Molecular cell 1999;4(6):1029-40.
1999: Waterman H; Levkowitz G; Alroy I; Yarden Y
The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor.
The Journal of biological chemistry 1999;274(32):22151-4.
1999: Waterman H; Alroy I; Strano S; Seger R; Yarden Y
The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.
The EMBO journal 1999;18(12):3348-58.
1999: Harari D; Tzahar E; Romano J; Shelly M; Pierce J H; Andrews G C; Yarden Y
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.
Oncogene 1999;18(17):2681-9.
1999: Klapper L N; Glathe S; Vaisman N; Hynes N E; Andrews G C; Sela M; Yarden Y
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(9):4995-5000.
1999: Alroy I; Soussan L; Seger R; Yarden Y
Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor.
Molecular and cellular biology 1999;19(3):1961-72.
1998: Levkowitz G; Waterman H; Zamir E; Kam Z; Oved S; Langdon W Y; Beguinot L; Geiger B; Yarden Y
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.
Genes & development 1998;12(23):3663-74.
1998: Chausovsky A; Tsarfaty I; Kam Z; Yarden Y; Geiger B; Bershadsky A D
Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells.
Molecular biology of the cell 1998;9(11):3195-209.
1998: Tzahar E; Moyer J D; Waterman H; Barbacci E G; Bao J; Levkowitz G; Shelly M; Strano S; Pinkas-Kramarski R; Pierce J H; Andrews G C; Yarden Y
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.
The EMBO journal 1998;17(20):5948-63.
1998: Pinkas-Kramarski R; Shelly M; Guarino B C; Wang L M; Lyass L; Alroy I; Alimandi M; Kuo A; Moyer J D; Lavi S; Eisenstein M; Ratzkin B J; Seger R; Bacus S S; Pierce J H; Andrews G C; Yarden Y;
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.
Molecular and cellular biology 1998;18(10):6090-101.
1998: Lenferink A E; Pinkas-Kramarski R; van de Poll M L; van Vugt M J; Klapper L N; Tzahar E; Waterman H; Sela M; van Zoelen E J; Yarden Y
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.
The EMBO journal 1998;17(12):3385-97.
1998: Waterman H; Sabanai I; Geiger B; Yarden Y
Alternative intracellular routing of ErbB receptors may determine signaling potency.
The Journal of biological chemistry 1998;273(22):13819-27.
1998: Shelly M; Pinkas-Kramarski R; Guarino B C; Waterman H; Wang L M; Lyass L; Alimandi M; Kuo A; Bacus S S; Pierce J H; Andrews G C; Yarden Y
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes.
The Journal of biological chemistry 1998;273(17):10496-505.
1998: Pinkas-Kramarski R; Lenferink A E; Bacus S S; Lyass L; van de Poll M L; Klapper L N; Tzahar E; Sela M; van Zoelen E J; Yarden Y
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Oncogene 1998;16(10):1249-58.
1998: Tzahar E; Yarden Y
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands.
Biochimica et biophysica acta 1998;1377(1):M25-37.
1998: Eilam R; Pinkas-Kramarski R; Ratzkin B J; Segal M; Yarden Y
Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1888-93.
1997: Pinkas-Kramarski R; Eilam R; Alroy I; Levkowitz G; Lonai P; Yarden Y
Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation.
Oncogene 1997;15(23):2803-15.
1997: Tzahar E; Pinkas-Kramarski R; Moyer J D; Klapper L N; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin B J; Sela M; Andrews G C; Yarden Y
Bivalence of EGF-like ligands drives the ErbB signaling network.
The EMBO journal 1997;16(16):4938-50.
1997: Alroy I; Yarden Y
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions.
FEBS letters 1997;410(1):83-6.
1997: Klapper L N; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
Oncogene 1997;14(17):2099-109.
1997: Pinkas-Kramarski R; Alroy I; Yarden Y
ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.
Journal of mammary gland biology and neoplasia 1997;2(2):97-107.
1996: Tzahar E; Waterman H; Chen X; Levkowitz G; Karunagaran D; Lavi S; Ratzkin B J; Yarden Y
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.
Molecular and cellular biology 1996;16(10):5276-87.
1996: Aronica M G; Brizzi M F; Dentelli P; Rosso A; Yarden Y; Pegoraro L
p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells.
Oncogene 1996;13(5):1017-26.
1996: Pinkas-Kramarski R; Shelly M; Glathe S; Ratzkin B J; Yarden Y
Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations.
The Journal of biological chemistry 1996;271(32):19029-32.
1996: Bacus S S; Yarden Y; Oren M; Chin D M; Lyass L; Zelnick C R; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli R R; Hynes N E; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Oncogene 1996;12(12):2535-47.
1996: Pinkas-Kramarski R; Soussan L; Waterman H; Levkowitz G; Alroy I; Klapper L; Lavi S; Seger R; Ratzkin B J; Sela M; Yarden Y
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
The EMBO journal 1996;15(10):2452-67.
1996: Levkowitz G; Klapper L N; Tzahar E; Freywald A; Sela M; Yarden Y
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.
Oncogene 1996;12(5):1117-25.
1996: Chen X; Levkowitz G; Tzahar E; Karunagaran D; Lavi S; Ben-Baruch N; Leitner O; Ratzkin B J; Bacus S S; Yarden Y
An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.
The Journal of biological chemistry 1996;271(13):7620-9.
1996: Brizzi M F; Aronica M G; Rosso A; Bagnara G P; Yarden Y; Pegoraro L
Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes.
The Journal of biological chemistry 1996;271(7):3562-7.
1996: Bacus S S; Chin D; Yarden Y; Zelnick C R; Stern D F
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.
The American journal of pathology 1996;148(2):549-58.
1996: Karunagaran D; Tzahar E; Beerli R R; Chen X; Graus-Porta D; Ratzkin B J; Seger R; Hynes N E; Yarden Y
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
The EMBO journal 1996;15(2):254-64.
1995: Beerli R R; Graus-Porta D; Woods-Cook K; Chen X; Yarden Y; Hynes N E
Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.
Molecular and cellular biology 1995;15(12):6496-505.
1995: Blechman J M; Yarden Y
Structural aspects of receptor dimerization. c-kit as an example.
Annals of the New York Academy of Sciences 1995;766():344-62.
1995: Marikovsky M; Lavi S; Pinkas-Kramarski R; Karunagaran D; Liu N; Wen D; Yarden Y
ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes.
Oncogene 1995;10(7):1403-11.
1995: Karunagaran D; Tzahar E; Liu N; Wen D; Yarden Y
Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases.
The Journal of biological chemistry 1995;270(17):9982-90.
1995: Hurwitz E; Stancovski I; Sela M; Yarden Y
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(8):3353-7.
1995: Marte B M; Jeschke M; Graus-Porta D; Taverna D; Hofer P; Groner B; Yarden Y; Hynes N E
Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells.
Molecular endocrinology (Baltimore, Md.) 1995;9(1):14-23.
1995: Blechman J M; Lev S; Barg J; Eisenstein M; Vaks B; Vogel Z; Givol D; Yarden Y
The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction.
Cell 1995;80(1):103-13.
1994: Bacus S S; Zelnick C R; Chin D M; Yarden Y; Kaminsky D B; Bennington J; Wen D; Marcus J N; Page D L
Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior.
The American journal of pathology 1994;145(6):1337-48.
1994: Brizzi M F; Zini M G; Aronica M G; Blechman J M; Yarden Y; Pegoraro L
Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase.
The Journal of biological chemistry 1994;269(50):31680-4.
1994: Bacus S S; Zelnick C R; Plowman G; Yarden Y
Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.
American journal of clinical pathology 1994;102(4 Suppl 1):S13-24.
1994: Pinkas-Kramarski R; Eilam R; Spiegler O; Lavi S; Liu N; Chang D; Wen D; Schwartz M; Yarden Y
Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(20):9387-91.
1994: Ben-Levy R; Paterson H F; Marshall C J; Yarden Y
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.
The EMBO journal 1994;13(14):3302-11.
1994: Ben-Baruch N; Yarden Y
Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1994;206(3):221-7.
1994: Brizzi M F; Blechman J M; Cavalloni G; Givol D; Yarden Y; Pegoraro L
Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells.
Oncogene 1994;9(6):1583-9.
1994: Stancovski I; Sela M; Yarden Y
Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase.
Cancer treatment and research 1994;71():161-91.
1994: Lev S; Blechman J M; Givol D; Yarden Y
Steel factor and c-kit protooncogene: genetic lessons in signal transduction.
Critical reviews in oncogenesis 1994;5(2-3):141-68.
1993: Peles E; Yarden Y
Neu and its ligands: from an oncogene to neural factors.
BioEssays : news and reviews in molecular, cellular and developmental biology 1993;15(12):815-24.
1993: Stancovski I; Schindler D G; Waks T; Yarden Y; Sela M; Eshhar Z
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(11):6577-82.
1993: Blechman J M; Lev S; Givol D; Yarden Y
Structure-function analyses of the kit receptor for the steel factor.
Stem cells (Dayton, Ohio) 1993;11 Suppl 2():12-21.
1993: Lev S; Blechman J; Nishikawa S; Givol D; Yarden Y
Interspecies molecular chimeras of kit help define the binding site of the stem cell factor.
Molecular and cellular biology 1993;13(4):2224-34.
1993: Peles E; Ben-Levy R; Tzahar E; Liu N; Wen D; Yarden Y
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.
The EMBO journal 1993;12(3):961-71.
1993: Orr-Urtreger A; Trakhtenbrot L; Ben-Levy R; Wen D; Rechavi G; Lonai P; Yarden Y
Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(5):1867-71.
1993: Blechman J M; Lev S; Brizzi M F; Leitner O; Pegoraro L; Givol D; Yarden Y
Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor.
The Journal of biological chemistry 1993;268(6):4399-406.
1993: Kelman Z; Simon-Chazottes D; Guénet J L; Yarden Y
The murine vik gene (chromosome 9) encodes a putative receptor with unique protein kinase motifs.
Oncogene 1993;8(1):37-44.
1992: Hadari Y R; Tzahar E; Nadiv O; Rothenberg P; Roberts C T; LeRoith D; Yarden Y; Zick Y
Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers.
The Journal of biological chemistry 1992;267(25):17483-6.
1992: Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y
Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
The Journal of steroid biochemistry and molecular biology 1992;43(1-3):95-103.
1992: Lev S; Yarden Y; Givol D
Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor.
The Journal of biological chemistry 1992;267(22):15970-7.
1992: Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
The Journal of biological chemistry 1992;267(24):17304-13.
1992: Gokkel E; Grossman Z; Ramot B; Yarden Y; Rechavi G; Givol D
Structural organization of the murine c-kit proto-oncogene.
Oncogene 1992;7(7):1423-9.
1992: Peles E; Lamprecht R; Ben-Levy R; Tzahar E; Yarden Y
Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.
The Journal of biological chemistry 1992;267(17):12266-74.
1992: Lev S; Yarden Y; Givol D
A recombinant ectodomain of the receptor for the stem cell factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses.
The Journal of biological chemistry 1992;267(15):10866-73.
1992: Bacus S S; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills G B; Ullrich A; Sela M; Yarden Y
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Cancer research 1992;52(9):2580-9.
1992: Yayon A; Zimmer Y; Shen G H; Avivi A; Yarden Y; Givol D
A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold.
The EMBO journal 1992;11(5):1885-90.
1992: Hemmerich S; Yarden Y; Pecht I
A cromoglycate binding protein from rat mast cells of a leukemia line is a nucleoside diphosphate kinase.
Biochemistry 1992;31(19):4574-9.
1992: Peles E; Bacus S S; Koski R A; Lu H S; Wen D; Ogden S G; Levy R B; Yarden Y
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.
Cell 1992;69(1):205-16.
1992: Lev S; Givol D; Yarden Y
Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(2):678-82.
1991: Orr-Urtreger A; Givol D; Yayon A; Yarden Y; Lonai P
Developmental expression of two murine fibroblast growth factor receptors, flg and bek.
Development (Cambridge, England) 1991;113(4):1419-34.
1991: Stancovski I; Hurwitz E; Leitner O; Ullrich A; Yarden Y; Sela M
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(19):8691-5.
1991: Peles E; Levy R B; Or E; Ullrich A; Yarden Y
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
The EMBO journal 1991;10(8):2077-86.
1991: Avivi A; Zimmer Y; Yayon A; Yarden Y; Givol D
Flg-2, a new member of the family of fibroblast growth factor receptors.
Oncogene 1991;6(6):1089-92.
1991: Raz V; Kelman Z; Avivi A; Neufeld G; Givol D; Yarden Y
PCR-based identification of new receptors: molecular cloning of a receptor for fibroblast growth factors.
Oncogene 1991;6(5):753-60.
1991: Yarden Y; Peles E
Biochemical analysis of the ligand for the neu oncogenic receptor.
Biochemistry 1991;30(14):3543-50.
1991: Lev S; Givol D; Yarden Y
A specific combination of substrates is involved in signal transduction by the kit-encoded receptor.
The EMBO journal 1991;10(3):647-54.
1990: Yarden Y
Receptor-like oncogenes: functional analysis through novel experimental approaches.
Molecular immunology 1990;27(12):1319-24.
1990: Goldman R; Levy R B; Peles E; Yarden Y
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation.
Biochemistry 1990;29(50):11024-8.
1990: Lev S; Yarden Y; Givol D
Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene.
Molecular and cellular biology 1990;10(11):6064-8.
1990: Orr-Urtreger A; Avivi A; Zimmer Y; Givol D; Yarden Y; Lonai P
Developmental expression of c-kit, a proto-oncogene encoded by the W locus.
Development (Cambridge, England) 1990;109(4):911-23.
1990: Safran A; Avivi A; Orr-Urtereger A; Neufeld G; Lonai P; Givol D; Yarden Y
The murine flg gene encodes a receptor for fibroblast growth factor.
Oncogene 1990;5(5):635-43.
1990: Yarden Y
Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(7):2569-73.
1988: Seger R; Yarden Y; Kashles O; Goldblatt D; Schlessinger J; Shaltiel S
The epidermal growth factor receptor as a substrate for a kinase-splitting membranal proteinase.
The Journal of biological chemistry 1988;263(7):3496-500.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Yosef Yarden

Research Profile (preview)

Chemicals & Drugs

Physiology

Living Beings

Phenomena

Concepts & Ideas

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Yosef Yarden (preview)

All Publications